SorCS1 inhibits amyloid-β binding to neurexin and rescues amyloid-β–induced synaptic pathology
Life Science Alliance · 2023-04 · 6 (4) · e202201681
DOI: 10.26508/lsa.202201681 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 25.01.2023. Verfasst von Alfred Kihoon Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Synapse Development and Plasticity Research Unit, Institut de Recherches Cliniques de Montréal, Montreal, Canada. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Receptors, Cell Surface. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada, FRQ | Fonds de Recherche du Québec-Société et Culture.
Abstract (Originalsprache)
Amyloid-β oligomers (AβOs), toxic peptide aggregates found in Alzheimer’s disease, cause synapse pathology. AβOs interact with neurexins (NRXs), key synaptic organizers, and this interaction dampens normal trafficking and function of NRXs. Axonal trafficking of NRX is in part regulated by its interaction with SorCS1, a protein sorting receptor, but the impact of SorCS1 regulation of NRXs in Aβ pathology was previously unstudied. Here, we show competition between the SorCS1 ectodomain and AβOs for β-NRX binding and rescue effects of the SorCS1b isoform on AβO-induced synaptic pathology. Like AβOs, the SorCS1 ectodomain binds to NRX1β through the histidine-rich domain of NRX1β, and the SorCS1 ectodomain and AβOs compete for NRX1β binding. In cultured hippocampal neurons, SorCS1b colocalizes with NRX1β on the axon surface, and axonal expression of SorCS1b rescues AβO-induced impairment of NRX-mediated presynaptic organization and presynaptic vesicle recycling and AβO-induced structural defects in excitatory synapses. Thus, our data suggest a role for SorCS1 in the rescue of AβO-induced NRX dysfunction and synaptic pathology, providing the basis for a novel potential therapeutic strategy for Alzheimer’s disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Synapse Development and Plasticity Research Unit, Institut de Recherches Cliniques de Montréal, Montreal, Canada.
- Integrated Program in Neuroscience, McGill University, Montreal, Canada.
- Department of Medicine, Université de Montréal, Montreal, Canada.
- Synapse Development and Plasticity Research Unit, Institut de Recherches Cliniques de Montréal, Montreal, Canada Hideto.Takahashi@ircm.qc.ca.
- Division of Experimental Medicine, McGill University, Montreal, Canada.
ORCID-Profile: Hideto Takahashi
Förderung
- CIHR
- Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada
- FRQ | Fonds de Recherche du Québec-Société et Culture
- Institut de Recherche Clinique De Montréal
- McGill University
- Société Alzheimer | Alzheimer Society Research Program
- FRQ | Fonds de Recherche du Québec - Santé
- Gouvernement du Canada | Canadian Institutes of Health Research
Zitieren
APA
Lee, A. K., Yi, N., Khaled, H., Feller, B., & Takahashi, H. (2023). SorCS1 inhibits amyloid-β binding to neurexin and rescues amyloid-β–induced synaptic pathology. Life Science Alliance, 6(4), e202201681. https://doi.org/10.26508/lsa.202201681
Vancouver
Lee AK, Yi N, Khaled H, Feller B, Takahashi H. SorCS1 inhibits amyloid-β binding to neurexin and rescues amyloid-β–induced synaptic pathology. Life Science Alliance. 2023;6(4):e202201681. doi:10.26508/lsa.202201681
BibTeX
@article{Lee2023,
author = {Lee, Alfred Kihoon and Yi, Nayoung and Khaled, Husam and Feller, Benjamin and Takahashi, Hideto},
title = {SorCS1 inhibits amyloid-β binding to neurexin and rescues amyloid-β–induced synaptic pathology},
journal = {Life Science Alliance},
year = {2023},
volume = {6},
number = {4},
pages = {e202201681},
doi = {10.26508/lsa.202201681}
}
EUVIMED